In our hands, mining of the Oncomine database revealed that SMYD2 transcription is significantly elevated in patients with bladder cancer, colon adenoma and colorectal carcinoma, hepatocellular carcinoma, prostate carcinoma, hereditary clear cell renal cell carcinoma, and chronic lymphocytic leukemia (OncomineTM; Compendia Bioscience, Ann Arbor, MI). This evidence concerns the gene SMYD2 and urinary bladder cancer.